BeiGene Announces FDA Accelerated Approval of Brukinsa for the Treatment of Relapsed or Refractory Follicular Lymphoma

BASEL, Switzerland& BEIJING& CAMBRIDGE, Mass.-- Mar 07, 2024 (BUSINESS WIRE)-- BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news